Up-front Cash/Equity Payment of $60M
Baxter, Cell Therapeutics Sign JAK[ed] Up Myelofibrosis Deal
By Catherine Shaffer
Friday, November 15, 2013
Fresh from a special protocol assessment agreement with the FDA, Cell Therapeutics Inc. has snagged a lucrative licensing deal with Baxter International Inc. for its Janus kinase (JAK) inhibitor, pacritinib.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.